Propanc Biopharma, Inc.
PPCB· Nasdaq
PPCBPropanc Biopharma, Inc.
Filed May 15, 2024 · 10-Q · 45 days after period end · 0001493152-24-019940
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Net Income | -$526.70K | -$809.81K | -$462.69K | -$417.74K |
| EPS Diluted | -$545.79 | -$0.42 | — | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end
